Theranexus Société Anonyme Valuation

Q: What is the Fair Price of ALTHX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ALTHX (€0.51) is trading below our estimate of [[fair value]] (€1.04)

Is ALTHX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALTHX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALTHX (€0.51) is trading below our estimate of fair value (€1.04)

Significantly Below Fair Value: ALTHX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALTHX?

Key metric: As ALTHX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALTHX. This is calculated by dividing ALTHX's market cap by their current revenue.
What is ALTHX's PS Ratio?
PS Ratio	1.7x
Sales	€2.27m
Market Cap	€4.00m

ALTHX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.3x
Enterprise Value/EBITDA	-1.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ALTHX's PS Ratio compare to its peers?

The above table shows the PS ratio for ALTHX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	15.2x
ALDVI Advicenne	7.8x	31.8%	€26.3m
AB AB Science	47.6x	n/a	€53.6m
HERB Herbal Dispatch	0.5x	n/a	CA$4.5m
IXC Invex Therapeutics	4.7x	n/a	AU$5.7m
ALTHX Theranexus Société Anonyme	1.7x	n/a	€4.0m

Price-To-Sales vs Peers: ALTHX is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (15.2x).

Price to Sales Ratio vs Industry

How does ALTHX's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

23 Companies	Price / Sales	Estimated Growth	Market Cap

23 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ALTHX is good value based on its Price-To-Sales Ratio (1.7x) compared to the European Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is ALTHX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALTHX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALTHX's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Euroapi

€322.0m

Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use.

EAPI

€3.41

-5.9%

-36.3%

Sanofi

€113.8b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€90.80

-3.4%

6.9%

Eurofins Scientific

€8.7b

Provides various analytical testing and laboratory services worldwide.

ERF

€45.86

2.0%

-11.4%